Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 2Waldenstrom Macroglobulinemia 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 24Lenalidomide 12Cyclophosphamide 12fludarabine phosphate 10Peripheral Blood Stem Cell Transplantation 10Mycophenolic Acid 6Cyclosporine 6Whole-Body Irradiation 5Radiotherapy 5Filgrastim 5ibritumomab tiuxetan 4Indium 4Etoposide 4romidepsin 3Sirolimus 3Prednisone 3Pentostatin 3Methotrexate 3Melphalan 3In Situ Hybridization, Fluorescence 3Gene Expression Profiling 3Everolimus 3Busulfan 3Bortezomib 3Bendamustine Hydrochloride 3zanubrutinib 2venetoclax 2veltuzumab 2temsirolimus 2obinutuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, B-Cell, Marginal Zone × alethine × Clear all
NCT00007839 2013-12-18

Beta Alethine in Treating Patients With Low-Grade Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡